Oct 2026· JACC: Advances· Vol 5· 0 citations· 44 references
Medicine
TL;DR
Treatment selection should prioritize treatments with demonstrated superiority over baseline treatment, including spironolactone, baxdrostat, and radiofrequency renal denervation in patients with resistant or uncontrolled hypertension.
Abstract
Background Many patients with hypertension fail to achieve recommended blood pressure targets despite treatment with 2 or more antihypertensive drugs. Objectives We aimed to compare the efficacy of add-on treatments for the management of resistant or uncontrolled hypertension. Methods We searched Embase and MEDLINE through November 2025. We included randomized trials comparing add-on treatments for resistant or uncontrolled hypertension. The certainty of evidence was assessed using the Confidence In Network Meta-Analysis (CINeMA) framework. The primary outcome was the change in office systolic blood pressure from baseline. Summary mean differences were estimated using random-effects network meta-analysis within a Bayesian framework in patients with resistant hypertension and in the broader population with uncontrolled hypertension. Results We included 35 trials (8,648 patients and 12 individual treatments) in the systematic review and 30 trials (8,187 patients and 10 individual treatments) in the network meta-analysis. In patients with resistant hypertension, spironolactone (mean difference: −12.43 mm Hg; 95% credible interval: −17.68 to −7.18; CINeMA moderate) and radiofrequency renal denervation (mean difference: −8.74 mm Hg; 95% credible interval: −12.96 to −4.52; CINeMA moderate) were more effective than baseline treatment in reducing office systolic blood pressure. Similar findings were observed in patients with uncontrolled hypertension. No intervention demonstrated clear superiority over another because most head-to-head comparisons included the possibility of no effect. Conclusions In head-to-head comparisons, no significant differences were observed between add-on treatments in reducing blood pressure among patients with resistant or uncontrolled hypertension. Treatment selection should prioritize treatments with demonstrated superiority over baseline treatment, including spironolactone, baxdrostat, and radiofrequency renal denervation.
Baxdrostat was effective in lowering systolic blood pressure, but increased the risk of hyperkalemia, which supports it as an alternative therapy for uncontrolled and resistant hypertension, with cautious use in patients at risk for hyperkalemia.
A. Bortolotto, P. Goncalves, L. Bortolotto· European Heart Journal· 0 citations
Low-dose combination-based antihypertensive therapy has emerged as a promising strategy to improve blood pressure (BP) control while minimizing dose-related adverse effects. However, evidence comparing its efficacy and safety with conventional antihypertensive therapy remains limited. This systematic review and m...
Malaha Ali, M. Marofi, Muskaan Zehra et al.· BMC Cardiovascular Disorders· 0 citations
Addressing factors that contribute to pseudo-resistance is of utmost significance in managing a patient with apparent treatment resistance or even refractory hypertension in the primary care setting, and this work aims to address factors to improve care for hypertension in the primary care setting.
Vijay Joshi, Shreepriya Mangalgi, K. Chaudhary et al.· Journal of Osteopathic Medic...· 0 citations
Hypertension control remains challenging, particularly in patients treated with multiple antihypertensive classes. Identifying how uncontrolled patients differ from controlled patients, despite similar treatment intensity, may help improve management strategies.
To compare clinical and treatment characteri...
M. Camafort, A. Dzudie, J. Magne et al.· European Heart Journal· 0 citations
OBJECTIVE To evaluate the effectiveness of monotherapy versus combination therapy in controlling blood pressure in the elderly population in eastern Indonesia, i.e., Central Sulawesi.
METHODS This study used a cross-sectional design, examining secondary data from the medical records of inpatients with hypertension in a...
Ingrid Faustine, Yuliet Susanto, Ririen Hardani et al.· Biomedical Sciences and Clin...· 0 citations
Hypertension is a major cardiovascular risk factor. While SPRINT supported systolic blood pressure (SBP) <120 mmHg, ACCORD showed no similar benefit in diabetes. Recent trials raised safety concerns, leaving optimal SBP targets and the benefit-harm balance uncertain.
To evaluate the efficacy and safety of...
O. Ochoa, Y. C. Mayorga Parra, J. A. Laguna Duarte· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.